HK Stock Market Move | ANTON OILFIELD (03337) rose more than 5% in the early market, with revenue growth supported by light asset operations. Annual net profit increased by over 50% year-on-year.
Anton Oilfield Services (03337) surged by over 5% in the morning trading session. As of the time of publication, it increased by 5.61% to HK$1.13, with a transaction volume of HK$31.495 million.
ANTON OILFIELD (03337) rose more than 5% in early trading, rising by 5.61% at the time of writing, to HKD 1.13 with a turnover of HKD 314.953 million.
On the news front, ANTON OILFIELD recently released its annual performance, achieving an annual operating income of HKD 5.57 billion, a year-on-year increase of 17.2%; net profit attributable to shareholders was HKD 370 million, a year-on-year increase of 53.8%. The board of directors proposed a final dividend of HKD 0.0373 per share, compared to HKD 0.025 per share in the same period last year.
EB SECURITIES released a research report stating that in 2025, the company's integrated oilfield technology services, intelligent management services, and energy asset management businesses achieved operating incomes of HKD 2.48 billion, HKD 2.82 billion, and HKD 270 million, respectively, with year-on-year growth of 14.6%, 20.6%, and 8.2% respectively. The company's relatively light asset intelligent management service business revenue grew significantly, serving as a major driver of the company's performance growth. The bank pointed out that the company is experiencing steady growth in the domestic market and making breakthroughs in multiple overseas markets; however, changes in the situation in the Middle East may have a certain impact on the company's business development in the region.
Related Articles

Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

There is currently disagreement within OpenAI about when to IPO: Altman hopes for the fourth quarter, but the CFO believes they are not yet ready.
Jiangsu Aidea Pharmaceutical Group (688488.SH): A clinical trial for a new type 1 drug ACC085 injection in the field of HIV treatment will be conducted.

Subsidiary company of Shenzhen Nanshan Power (000037.SZ) plans to invest in the construction of a 300MW/600MWh independent energy storage power station in the Cuiheng New Area of Zhongshan City (Phases Two and Three) project.

There is currently disagreement within OpenAI about when to IPO: Altman hopes for the fourth quarter, but the CFO believes they are not yet ready.

RECOMMEND

Hong Kong Stocks Surge! Buying Opportunity Or Wait And See? Analysts Provide Comprehensive Interpretation
02/04/2026

Narrative Drives Everything As China’s AI Newcomers Enter An Era Of Extreme Volatility, Retail Investors Flood In
02/04/2026

Fund Cohort Stocks Rally As Institutional Confidence In Hong Kong Equities Shows Signs Of Repair
02/04/2026


